

04 Aug 2023

Bristol-Myers Squibb International Corporation

Email: Clinical.Trials@bms.com

Chaussée de la Hulpe 185

Brussels, Belgium

1170

EudraCT Number: 2018-003719-23  
Sponsor Protocol Number: CA209-9TN

A Phase 2 Multi-Center Randomized Trial to Assess Early Intervention with Adjuvant  
Nivolumab in Non-Small Cell Lung Cancer Participants with ctDNA-detected Minimal Residual  
Disease after Surgical Resection

(CheckMate 9TN: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9TN)

Trial (2018-003719-23) was withdrawn with 0 patients enrolled. As such no results are reported.